ABSTRACT
INTRODUCTION
In humans, epithelial carcinomas, including ovarian cancer, result from the accumulation of multiple genetic changes. Examples of common mutations include those in the p53 gene, mutated in 50 -70% of advanced ovarian cancers (1) . Missense mutation of p53 leads to accumulation of TP53 in at least 50% of ovarian cancers (2, 3) . Only 30% of ovarian cancers exhibit loss of heterozygosity at the Rb gene locus, and no mutations have been detected in the remaining Rb allele (4) . However, systematic analysis of the genes involved in the entire Rb pathway (p16-CDK4/cyclin D1-pRb) revealed that 80% of the human ovarian cancer specimens examined had abnormalities in this pathway (5) . Activation of the catalytic subunit of human telomerase reverse transcriptase (hTERT) is also common in human ovarian cancers (6 -8) . hTERT, which has been implicated in cellular immortalization and transformation, may play a critical role in human ovarian oncogenesis, although recent findings suggest that hTERT expression could facilitate long-term tumor growth rather than contributing directly to transformation (9) .
The RAS gene family has been implicated in the development of many human epithelial cancers. RAS genes encode highly homologous and evolutionarily conserved M r 21,000 GTP-binding proteins, which are often activated in human ovarian cancer. KRAS mutations have been found in 30% of borderline ovarian tumors and in a subset of invasive mucinous ovarian cancers (10 -15) . In one study, mutations in KRAS or its downstream mediator BRAF were detected in 68% of low-grade serous carcinomas and in 61% of borderline serous tumors, implicating the KRAS pathway in these tumors as well (16) . The oncogenic allele HRAS V12 is present in ϳ6% of ovarian cancers (15) . However, physiologically activated HRAS protein is commonly detected in human ovarian cancer, presumably because of an increase in upstream signals from tyrosine kinase growth factor receptors such as Her-2/neu, despite an absence of RAS mutation (17, 18) . The mechanisms by which ras oncogenes transform human epithelial cells are not clear.
Several investigators have cultured ovarian surface epithelial cells to use them as model system to study ovarian cancer development. Ovarian surface epithelial cells have been cultured from rats (19, 20) , mice (21, 22) , and rabbits (23) . A high proportion of rat ovarian surface epithelial cell cultures become spontaneously immortalized and are highly susceptible to K-ras transformation (19) . These spontaneously immortalized cells remained nontumorigenic even after introduction of the SV40 early region expressing large T and small t (T/t) antigens, but they became tumorigenic after transfection with HRAS (24) . Rat ovarian surface epithelial cell lines can also be transformed into tumorigenic cell lines through multiple passages in vitro (20, 25) . In another approach, Orsulic et al. (26) used an avian retrovirus to introduce c-Myc, K-ras, or Akt into murine ovarian surface epithelial cells and found that introduction two of these oncogenes into cells with a mutated p53 led to the formation of murine ovarian tumors that were similar to human ovarian carcinomas. A more recent study showed that about half of female transgenic mice expressing the transforming region of SV40 under the control of the Mullerian inhibitory substance type II receptor gene promoter developed bilateral ovarian tumors (27) .
The biological differences between human cells and rodent cells make extrapolating results from mice or rats to humans difficult. Ovarian surface epithelial cells from humans are much more difficult to transform than are such cells from rodents. Several laboratories have used cultured human ovarian surface epithelial cells to study human ovarian carcinogenesis (28 -31) . Transfection of such cells with the SV40 T/t or the human papillomavirus type 16 E6/E7 region (29, 32) can extend their life span, but the transfected cells eventually enter crisis and die. After several months, immortal cells occasionally emerge but do not form colonies in soft agar or tumors in nude mice (29, 32) . Very rarely, cells transfected with T/t or E6/E7, after many passages in tissue culture, can produce colonies in soft agar or form tumors in nude mice (29, 30) , presumably as a result of spontaneous mutation. Recently, several nonovarian primary human epithelial and fibroblast cells have been successfully transformed by using a combination of the SV40 T/t, hTERT, and HRAS V12 (33, 34) . Whether a similar combination of genes is sufficient to transform human ovarian surface epithelial cells has not previously been addressed. In addition, the changes in the gene expression profile and the underlying molecular mechanisms associated with ras-mediated transformation in human cells have not been reported. The purpose of this study was to use specific genetic elements to disrupt the signaling pathways implicated in tumorigenesis in human ovarian surface epithelial cells, to assess the molecular mechanisms used by the ras oncoprotein at the genomic level, and to propose a genetic model of the pathophysiology of human ovarian cancer.
MATERIALS AND METHODS
Generation of Cell Lines. Human ovarian surface epithelial cells that had previously been transfected with the SV40 early region expressing large T and small t antigens (IOSE-80 and IOSE-29) are described elsewhere (28, 35) . The SV40 T/t antigen inactivates both the p53 and pRb pathways and extends the life span of these cells to 10 passages while maintaining many of the properties of normal ovarian epithelium. For this study, 10 4 cells were cultured in 6-cm dishes with 3 ml of ovarian epithelial-cell culture medium consisting of 1:1 MCDB 105 medium (Sigma-Aldrich Co., St. Louis, MO) and Cellgro Medium 199 (Mediatech, Inc., Herndon, VA) with 10% fetal bovine serum (Intergen, Sunnyvale, CA), 2 mM L-glutamine (Mediatech), 10 units/ml penicillin/ streptomycin, and 10 ng/ml epidermal growth factor (28) . The IOSE-29 (passage 14) and IOSE-80 (passage 14) cells were infected sequentially, first with retrovirus containing a full-length hTERT cDNA (to generate the T80 and T29 cell lines) and next with pBabe-puro-HRAS V12 (to create the T80H and T29H cell lines). Briefly, amphotropic retroviral packaging phoenix cells (a gift from Dr. Gary Nolan, Stanford University) were transfected with pBabe-hygro-hTERT or pBabe-puro-HRAS V12 or pLNCX-KRAS V12 by calcium precipitation, and the resulting supernatants were used to infect the SV40 T/t-transfected ovarian epithelial cells. Infected cells were selected in hygromycin (100 g/ml for 7 days) and puromycin (0.5 g/ml for 5 days). A third human ovarian surface epithelial cell line, OSE 72, was initiated from normal human ovarian surface epithelial cells and infected sequentially with pBabezeocin-SV40 T/t, hTERT, and HRAS V12 , or KRAS V12 . The detailed protocol for retrovirus production has been described elsewhere (36) . The antibodies used to detect RAS were from Santa Cruz Biotechnology Inc. Rabbit polyclonal, C20 (SC-520) for HRAS, 1:2000 dilution; mouse monoclonal IgG 2 , F234 (SC30) for KRAS, 1:1000 dilution. Western blot was carried out as previously described (36, 37) .
Telomerase Assay. Telomerase activity was measured with the TRAPeze telomerase detection kit (Oncor, Inc., Gaithersburg, MD) as originally described by Kim and Wu (38) .
Clonogenicity Assay. Cells (10 5 ) were suspended in 2 ml of ovarian epithelial cell medium with 0.35% agarose (Life Technologies, Inc. Rockville, MD), and the suspension was placed on top of 5 ml of solidified 0.7% agarose. Triplicate cultures for each cell type were maintained for 14 days at 37°C on atmosphere of 5% CO 2 and 95% air, and fresh medium was added after 1 week. Colonies Ͼ 50 m in diameter were counted after 2 weeks. These experiments were repeated twice.
Tumor Formation in nu/nu Mice. Equal numbers (5 ϫ 10 6 ) of IOSE-80, T80, and T80H cells (or IOSE-29, T29, and T29H cells) were harvested by trypsinization, washed twice with 1ϫ PBS, resuspended in 0.1 ml of saline, and injected either s.c or i.p. into 4 -6-week-old BALB/c athymic nude mice (The Jackson Laboratory, Bar Harbor, ME). SKOV-3 ovarian cancer cells were used as a positive control. The mice were kept in a pathogen-free environment and checked every 2 days for 5 months. Mice given i.p. injections were observed for lethargy, poor appetite, and abdominal enlargement. The date at which the first grossly visible tumor appeared was recorded, and tumor size was measured every 2 days thereafter. Mice were killed when tumors reached 1.5 cm in diameter. Tumors were removed and fixed in 10% formalin overnight and subjected to routine histological examination.
Immunohistochemical Analysis. Tissue sections were deparaffinized and dehydrated, intrinsic peroxidase activity was blocked with a 3% solution of hydrogen peroxide in methanol, and immunostaining was performed with an automated immunohistochemical staining machine (Dako, Carpinteria, CA) and an avidin-biotin-peroxidase enzyme complex using antibodies specific for p53 ( Gene Expression Array and Data Analysis. RNA was extracted with TRIZOL reagent (Invitrogen) and purified with the RNeasy Kit (Qiagen). The Affymetrix GeneChip Human Genome U133 series of oligoarrays (Affymetrix, Santa Clara, CA) were used to measure gene expression. This series tests the expression of Ͼ29,297 human genes and expressed sequence tags. Preparation of biotinylated cRNA, hybridization, and scanning of the microarrays were performed according to the manufacturer's protocols. Data were collected by using GeneChip software (Affymetrix) and analyzed with the software program dChip (39, 40) . We used version 1.2 with the perfect match only model to estimate differences. The genes listed in Table 1 exhibited a 2.5-fold change and had to show consistent change in at least three of the six RAS-transformed (either HRAS V12 or KRAS V12 ) cell lines. Transient Transfection and Assay of Promoter Activity. Nuclear factor (NF)-B activity was measured by reporter plasmids that contained two copies of the wild-type NF-B binding site or two copies of mutated NF-B binding sites ligated to luciferase reporters. Transcriptional activation of interleukin (IL)-8 by NF-B was investigated by using a wild-type IL-8 promoter (Ϫ146 to ϩ1) and a promoter that contained a mutated NF-B binding site (41) . Luciferase activity was measured 48 h after transfection. A total of 4 g of plasmid was used in each transfection. Activity was normalized against ␤-galactosidase activity. Luciferase activity was assayed with Promega's (Madison, WI) luciferase reporter assay system. Preparation of Nuclear Extracts and Labeling of the Oligonucleotide and Electrophoretic Mobility Shift Assay. Nuclear extract preparation was performed as described previously. Labeling of the oligonucleotide and electrophoretic mobility shift assay was performed according to manufacture's instruction (Gelshift NF-B p50 kit from Active Motif Co., Carlsbad, CA; Refs. [41] [42] [43] .
Induction of Apoptosis by Antibody Treatment. T29, T80, T29H, T29K, T80H, and T80K cells (2 ϫ 10 5 ) were grown in serum-free RPMI medium for 24 h, after which, 2 g/ml monoclonal antibody against IL-1␤ or IL-8 (Sigma-Aldrich, MO) were added and the cells incubated without serum or antibiotics. Cells were harvested at 8, 16, 24, 48, and 72 h after the addition of antibody and stained with the Annexin V-fluorescence apoptosis detection kit I (Roche) and with propidium iodide, after which, cell apoptosis was analyzed with a FACStation (BD Biosciences) equipped with CellQuest software. The percentage of apoptotic cells was calculated in terms of peaks (M 2 ) in the histogram, representing an early apoptotic population among the total cells analyzed.
RESULTS
Human Ovarian Surface Epithelial Cells Can Be Immortalized by SV40 T/t and hTERT. We introduced hTERT into two human ovarian surface epithelial cell lines (IOSE-80 and IOSE-29) that had previously been transfected with SV40 T/t antigens. The resulting cell lines, denoted T80 and T29, grew continuously for Ͼ200 days, consistent with being immortalized. The parental IOSE-80 and IOSE-29 cells ceased proliferating after 30 -60 days in culture (Fig. 1, A and C) . Telomerase activity was detected in T80 and T29 cells (Fig. 1, B and D, Lane 3) but not in IOSE-80 or IOSE-29 cells (Fig. 1, B and D, Lane 1). Heat inactivation eliminated the telomerase activity in both the T80 and T29 cell lines (Fig. 1, B and D increased the levels of HRAS or KRAS protein (Fig. 2) and anchorage-independent cell growth ( Table 2 ). The tumorigenicity of these ras-transformed human ovarian surface epithelial cells was evaluated by s.c. or i.p. injection into nude mice. No tumors were observed in the 2 mice injected with parental cells (IOSE-80 or IOSE-29) or in the 12 mice injected with immortalized cells T80 or 6 mice injected T29 cells (Table 2) . By contrast, 5 of 6 mice given s.c. injections of T80H or T29H cells formed tumors with surface ulceration (Fig. 3A, arrow) , and 3 of 4 mice given i.p. injections of T80H cells developed ascites (Fig. 3 , B and D) or tumors that grew within the omentum (Fig. 3 , C, bottom arrow) or invaded the liver (Fig. 3, C, (Fig. 4A) , numerous mitoses (Fig. 4B, arrows) , and extensive necrosis (Fig. 4C, arrows) . Tumor cells stained positively for cytokeratin (Fig. 4D) , confirming their epithelial origin, and for WT-1 (Fig. 4E) , a marker of serous ovarian carcinoma. The cells also stained positively for p53 (Fig. 4F) , consistent with the presence of stabilized p53 protein induced by the SV40 T antigen. The tumors grown from T29H-inoculated cells showed morphology similar to high-grade sarcoma (data not shown). This is likely because of its parental cells, IOSE-29, which has elongated fibroblast morphology and did not stain with cytokeratin (35) . The undifferentiated carcinomas and sarcoma are negative for CA125 and mesothelin (data not shown).
Expression of KRAS V12 , in contrast, was much less efficient at inducing tumor formation. Only 2 of 6 mice given s.c. injections and 1 of 9 given i.p. injections of T80K cells developed tumors ( Table 2) . Injection of T29K cells produced only four s.c. tumors in 10 mice and one i.p. tumor in 4 mice ( Table 2) . Subcutaneous-injected T29K cells formed cystic structures in 3 of 6 mice within a week (Fig. 5B) . Intraperitoneal-injected T29K cells produced a polyploid, cauliflowershaped tumor (Fig. 5A ) that was undifferentiated (Fig. 5C ) and showed high nuclear pleomorphism (Fig. 5D, arrow) . Interestingly, peritoneal injection of T80K cells produced biphasic tumor with poorly differentiated carcinoma and sarcoma, similar to malignant mixed Mullerian tumor of ovary. The poorly differentiated carcinoma components invaded into adipose tissue (Fig. 5E ) and formed glandular-like structure (Fig. 5F, arrows) . Immunohistochemical staining of carcinoma cells are positive for cytokeratin (Fig. 5G) , CA125 (Fig. 5H) , and mesothelin (Fig. 5I) . ) to the corresponding control group (T80 or T29). 
RAS-Mediated Transformation Alters the mRNA Expression
Profile. To identify the genetic pathways involved in the rasmediated transformation of normal human ovarian epithelial cells, we compared gene expression profiles in three sets of immortalized cells, T29, T80, and T72, made to express or to not express HRAS or KRAS. Introduction of either the HRAS V12 or the KRAS V12 gene led to increases and decreases in the mRNA levels of different genes. When we defined the cutoff for a difference in gene expression as being at least a 2.5-fold change in mRNA relative to that of the parental immortalized cells and consistent change in at least three of the six RAS-transformed cell lines, only 30 genes were affected: 21 were up-regulated and 9 were down-regulated ( Table 1) . The genes most consistently up-regulated were those for IL-1␣, IL-1␤, IL-6, IL-8, IL-11, pre-B-cell colony-enhancing factor, prostaglandin-endoperoxide synthetase-2, Gro-1, and Gro-2. Other genes that were up-regulated mediate invasion and stromal remodeling (e.g., tissue factor inhibitor-2 and tissue inhibitors of matrix metalloproteinases 1 and 3). Down-regulated genes included those involved in stromal synthesis (e.g., collagen type III␣1 and type 1␣2), the proapoptotic insulin-like growth factor binding protein-3, and the antiangiogenic factor thrombospondin-1.
RAS-Transformed Cells Depend on Elevated Cytokine for Survival.
To validate the changes in mRNA revealed by the expression array analysis, we used Western blotting to assess the amounts of protein produced by two of the up-regulated genes (those for IL-1␤ and IL-8). IL-1␤ and IL-8 were highly expressed in the RAStransformed cells but not in the hTERT-immortalized T29 or T80 cells (Fig. 6) . To examine the functional significance of this up-regulation in IL-1␤ and IL-8 expression by RAS-mediated transformation, we treated immortalized cells and their RAS-transformed derivatives with monoclonal antibodies against IL-1␤ and IL-8 and quantified the apoptotic cells. Numbers of apoptotic cells markedly increased when the RAS-transformed T29H and T80H cells were treated with these antibodies relative to similar treatment of the immortalized, nontransformed T29 and T80 cells (Fig. 7) . Blocking IL-1␤ in this way markedly increased the percentage of apoptotic cells in the T29H and T80H lines (Fig. 7, B and E) ; blocking IL-8 showed a similar effect (Fig. 7, B and E) . The maximum effect of apoptosis is seen at 16 -24 row) . E, microscopic picture of poorly differentiated carcinoma invading adipose tissue (ϫ100) generated from peritoneal injection of T80K cells and formed glandular-like structure (F, arrows, ϫ200). The carcinoma cells stained positively with cytokeratin (G), CA125 (H), and mesothelin (I), two commonly secreted markers by naturally derived ovarian cancers. h, with longer incubations, and percentage of apoptotic cells is decreased, probably because of an optimal antibody and cytokine ratio at these time points. Antibodies against IL-1␤ and IL-8 also induced apoptosis in KRAS-transformed cells, although not to the same extent as in the HRAS transformed cells (Fig. 7, C and F) . These results may partially explain why the KRAS-transformed cells were less tumorigenic that the HRAS-transformed cells.
To further explore the role of IL-1␤ and IL-8 in the pathogenesis of human ovarian cancer, we examined the expression of IL-l␤ and IL-8 in the naturally derived ovarian cancer cell line SKOV-3, which we found in a separate study to express high levels of activated HRAS without oncogenic mutation (37) . SKOV-3 cells in which HRAS expression was knocked down by retrovirusmediated RNA interference against HRAS V12 showed marked decreases in IL-1␤ and IL-8 levels (Fig. 8, Lane 3) , whereas no change was detected in SKOV-3 cells infected with either an empty retroviral vector (Fig. 8, Lane 1) or a small interfering RNA against an HRAS with a mutated form of HRAS (Val 12 ; Fig. 8 , Lane 2). These findings indicate that increased level of HRAS without V 12 mutation plays a critical role in regulating cytokine expression, demonstrating that similar cytokine pathways are operative in a naturally derived ovarian cancer cell line as in our model.
RAS Activates Cytokine Expression through NF-B.
Because several of the cytokine genes up-regulated by ras transformation have binding sites for NF-B in their promoter regions, we reasoned that NF-B could be mediating the cytokine expression in the RAStransformed cells. To test this hypothesis, we used plasmids that contained two copies of a wild-type or a mutant NF-B binding site linked to a luciferase reporter. Incubating T29 and T80 cells with a retroviral expression vector for HRAS V12 produced a concentrationdependent increase in luciferase activity from cells with the NF-B reporter constructs but not from those with the mutant NF-B binding-site controls (Fig. 9, A) . Experiments with a plasmid containing the IL-8 promoter or an IL-8 promoter containing mutated NF-B binding sites produced similar results (Fig. 9B) . However, when plasmids were transfected into T29H and T80H cells (i.e., those that already contain a stably expressed HRAS retroviral vector), high levels of luciferase activity were observed with wild-type NF-B binding sites but not with mutant NF-B binding sites. Cells without the stably integrated HRAS V12 vector (T29 and T80) showed no elevation in luciferase activity (Fig. 9C ). These results demonstrate that increased NF-B activity was associated with activation of IL-8.
To further explore the participation of NF-B in transforming activity of RAS, we used EMSA to directly examine the binding activity of NF-B. T29 cells showed basal levels of NF-B binding activity (Fig. 9D, Lane 1) [the band at NF-B (p50)], similar to the levels produced by the positive control (Fig. 9D, Lane 4) ; this NF-B binding activity could be competed away by oligonucleotide containing a wild-type NF-B binding site (Fig. 9D, Lane 2) but not mutant oligonucleotide (Fig. 9D, Lane 3 ). There was a marked increase in NF-B binding activity in the HRAStransformed T29H cells (Fig. 9D, Lane 5 ) that could be competed away by the oligonucleotide containing a wild-type NF-B binding site (Fig. 9D, Lane 6) but not by an oligonucleotide containing the mutated site (Fig. 9D, Lane 7) . Similar results were found in T80 and T80H cells (Fig. 9D, Lanes 9 -16 ). These findings demonstrate that RAS transformation may be mediated through the transcription factor NF-B.
DISCUSSION
Despite advances in surgical cytoreduction and cytotoxic chemotherapy, the prognosis for patients with ovarian cancer remains poor. Marked heterogeneity is a hallmark of the disease, not only in tumor histotype and grade but also in response to chemotherapy and overall prognosis. Efforts to elucidate the basis for this heterogeneity and the mechanisms that underlie the initiation and progression of ovarian cancer have been hampered by lack of a relevant laboratory model for this disease. The human ovarian cancer model system described here, unlike those of previous studies, is derived from well-defined genetic elements. Although the first of these elements, the SV40 T/t antigens, does not correspond directly to genes that are mutated in human ovarian cancer, the regulatory pathways that T antigen disrupts, particularly p53 and Rb, are commonly affected in ovarian cancer. With regard to hTERT, the second element used in these experiments, most ovarian cancers maintain telomere length as a consequence of telomerase activation (6 -8) . The ectopic expression of telomerase in this study thus mimics the increase in hTERT expression that occurs during the progression of spontaneously arising ovarian cancers. As for the third genetic element used, mutations in the HRAS gene in human ovarian cancer are rare, but mutations in KRAS are relatively common, especially in mucinous and low-grade serous ovarian tumors. Moreover, activation of RAS signaling pathways is common in ovarian cancer (17) , in part, as a consequence of autocrine stimulation of known upstream activators such as the epidermal growth factor receptor Her-2/neu (18) . We recently showed that HRAS protein was highly expressed in the human ovarian cancer cell line SKOV-3 and that knockdown of HRAS mRNA by retrovirus-mediated RNA silencing increased apoptosis and decreased the anchorage-independent growth and tumor growth of these cells (37) . Ovarian cancer is a heterogeneous disease with multiple histologies, including serous, mucinous, endometrioid, clear cells, undifferentiated, malignant mixed Mullerian tumor, and transitional cell types. Each of these tumors may share some common but a distinct pathway for their tumor development. Heterografts of T80H resembled high-grade undifferentiated tumor or poorly differentiated carcinoma of ovary. The tumor produced from the T80K cells resembles mixed malignant Mullerian tumor of ovary with carcinoma components stained positive for CA125 and mesothelin, two common markers secreted by naturally derived human ovarian cancer. Thus, the genetic elements we introduced into the human ovarian surface epithelial cells described here represent the first genetically defined model in which the genetic pathways disrupted are also disrupted in at least some fraction of naturally occurring human ovarian cancers. A previously reported model of ovarian cancer thought to have arisen through defined genetic alterations (44) was subsequently found to be a hybrid between ovarian surface epithelial cells and the human ovarian carcinoma line OVCAR3.
RAS exerts its effects through multiple downstream signal transduction pathways (45, 46) . Analysis of changes in the expression of RAS-mediated genes can provide new insight into the pathways involved in RAS-mediated transformation. Previous studies have used NIH-3T3, an immortalized mouse fibroblast line or naturally occur- ring cancer cells to examine the mRNA changes associated with RAS-mediated transformation (47, 48) . Extrapolating results from mice to humans, however, requires great caution; oncogenes that can transform rodent cells have repeatedly failed to transform human cells (49) , and RAS seems to use different mediators in transforming human cells and rodent cells (50) . In our study, a large fraction of the genes overexpressed as a consequence of HRAS or KRAS activation were for cytokines that are also involved in chronic inflammation and wound healing. Similarities between wound healing and tumor formation have long been hypothesized (51) . Increased concentrations of IL-1␤, IL-6, and IL-8 have been detected in human ovarian cancer cell lines (52) and in ascites and serum samples from patients with ovarian cancer (53) (54) (55) (56) , demonstrating that the pathways used in our genetically transformed cell lines are similar to those in naturally derived ovarian cancer. Furthermore, several of the up-regulated genes identified in our genetically transformed cells, including those superoxide dismutase 2, IL-6, tissue factor pathway inhibitor 2, and stanniocalcin 1, have also been identified independently by others (57) using expression array analysis of naturally derived human ovarian cancer tissue, demonstrating that our genetically defined model involves pathways that are dysregulated in naturally derived ovarian cancer.
Clinical features typical of ovarian cancer progression, including the spread of metastatic lesions over the peritoneal surface and the formation of "omental cake" that obstructs the bowel and invades the myenteric plexus, were mimicked in our model, as was the formation of ascites. Ascites can arise passively through occlusion of the diaphragmatic lymphatics by tumor cells, but nonobstructive mechanisms such as activation of a cytokine network in ras-mediated transformation may contribute as well. Our results demonstrate that NF-B was activated in ras-transformed ovarian epithelial cells and that this activation was responsible for the activation of IL-8, a regulator of angiogenesis, invasion, and metastasis and present in naturally derived cancer cell lines (58) . NF-B has also been implicated in tumorigenesis (59, 60) , in suppression of the p53-independent apoptosis induced by oncogenic ras (61) , and in HRAS-mediated transformation in rodent cells (41, 61, 63) . Blockade of the NF-B pathway has been shown to decrease tumor growth in ovarian cancer and other cancer cell lines (40, 42, 64) . These studies and our own work have demonstrated that both genetically transformed cells and naturally derived ovarian cancer cell lines use NF-B to activate cytokines, which facilitates the formation of tumor and ascites. Because ascites are associated with significant clinical morbidity, this model system may also be useful for testing strategies to limit malignant ascites.
In summary, we successfully transformed human ovarian surface epithelial cells with genetically defined elements that disrupt pathways that are often dysregulated in human ovarian cancer. Use of this system should permit identification of other oncogenic signals needed to transform normal ovarian epithelial cells, particularly these mimicked by the introduction of equivalent to SV40 T/t antigen, and allow the cooperative interaction of ovarian cancer genes to be tested in a genetically defined system. Understanding the molecular mechanisms of ras-mediated cytokine induction and their downstream targets will help to clarify the pathways in ovarian cancer development and help to identify new therapeutic and diagnostic targets.
